Logo image
Sign in
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer
Journal article

An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer

Peter G. Rose, Bradley J. Monk, Diane Provencher, Jean Hartney, Philippe Legenne and Stephen Lane
Gynecologic Oncology, Vol.120(1), pp.38-42
01/2011
PMID: 21055798

Metrics

3 Record Views

Details